Search Result

Results for "

cap-dependent endonuclease

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Influenza Virus (30) Isotope-Labeled Compounds (2)
By Research Areas:	Cancer (1) Infection (30)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Endonuclease Apical Sodium-Dependent Bile Acid Transporter CaMK CDK SNIPERs DNA-PK VDAC SGLT PDK-1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-143776

Cap-dependent endonuclease-IN-22	Influenza Virus	Infection
Cap-dependent endonuclease-IN-22 is a potent cap-dependent endonuclease (CEN) inhibitor .

HY-143762

Cap-dependent endonuclease-IN-12	Influenza Virus	Infection
Cap-dependent endonuclease-IN-12 (EXP-35) is a potent Cap-dependent endonuclease inhibitor with low cytotoxicity. Cap-dependent endonuclease-IN-12 shows inhibitory activity against H1N1 .

HY-143770

Cap-dependent endonuclease-IN-16	Influenza Virus	Infection
Cap-dependent endonuclease-IN-16 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-16 is a pyridone polycyclic derivative. Cap-dependent endonuclease-IN-16 has the potential for the research of influenza (extracted from patent CN112778330A, compound 15A) .

HY-143749

Cap-dependent endonuclease-IN-6	Influenza Virus	Infection
Cap-dependent endonuclease-IN-6 (compound 13) is a cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-6 shows inhibition against influenza virus (EC₅₀=38.21 nM) .

HY-143775

Cap-dependent endonuclease-IN-20	Influenza Virus	Infection
Cap-dependent endonuclease-IN-20 is a cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-20 shows antiviral activity against influenza virus A/Hanfang/359/95 (H3N2) with IC₅₀ of 4.82 μM (CN112940009A; DSC801) .

HY-143771

Cap-dependent endonuclease-IN-17	Influenza Virus	Infection
Cap-dependent endonuclease-IN-17 is a cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-17 shows antiviral activity against influenza virus A/Hanfang/359/95 (H3N2) with IC₅₀ of 1.29 μM (CN112898346A; DSC701) .

HY-143768

Cap-dependent endonuclease-IN-14	Influenza Virus	Infection
Cap-dependent endonuclease-IN-14 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-14 inhibits the replication of influenza virus. Cap-dependent endonuclease-IN-14 has the potential for the research of viral infections caused by influenza viruses (extracted from patent CN113620948A, compound 1-c) .

HY-143769

Cap-dependent endonuclease-IN-15	Influenza Virus	Infection
Cap-dependent endonuclease-IN-15 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-15 inhibits the replication of influenza virus. Cap-dependent endonuclease-IN-15 has the potential for the research of viral infections caused by influenza viruses (extracted from patent CN113226327A, compound c-1) .

HY-143781

Cap-dependent endonuclease-IN-26	Influenza Virus	Infection
Cap-dependent endonuclease-IN-26 is a cap-dependent endonuclease (CEN) inhibitor with an IC₅₀ of 286 nM. Cap-dependent endonuclease-IN-26 shows antiviral activity against many influenza A and B strains .

HY-144065

Cap-dependent endonuclease-IN-19	Influenza Virus	Infection
Cap-dependent endonuclease-IN-19 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-19 is a spirocyclic pyridone derivative. Cap-dependent endonuclease-IN-19 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent CN111410661A, compound 1) .

HY-144068

Cap-dependent endonuclease-IN-25	Influenza Virus	Infection
Cap-dependent endonuclease-IN-25 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-25 is a macrocyclic pyridotriazine derivative. Cap-dependent endonuclease-IN-25 has the potential for the research of viral infections caused by viruses belonging to the Orthomyxoviridae family (extracted from patent WO2020075080A1, compound 4) .

HY-143766

Cap-dependent endonuclease-IN-13	Influenza Virus	Infection
Cap-dependent endonuclease-IN-13 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-13 has the potential for the research of influenza virus infection (only influenza A) (extracted from patent WO2021180147A1, compound I-1) .

HY-144066

Cap-dependent endonuclease-IN-21	Influenza Virus	Infection
Cap-dependent endonuclease-IN-21 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-21 inhibits the replication of influenza virus. ap-dependent endonuclease-IN-21 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8B or 8A) .

HY-144067

Cap-dependent endonuclease-IN-23	Influenza Virus	Infection
Cap-dependent endonuclease-IN-23 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-23 inhibits the replication of influenza virus. ap-dependent endonuclease-IN-23 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8A or 8B) .

HY-143752

Cap-dependent endonuclease-IN-8	Influenza Virus	Infection
Cap-dependent endonuclease-IN-8 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-8 inhibits replication of orthomyxoviruses (including influenza A, influenza B and influenza C) (extracted from patent CN111410661A, compound I-196) .

HY-143747

Cap-dependent endonuclease-IN-5	Influenza Virus	Infection
Cap-dependent endonuclease-IN-5 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-5 inhibits influenza virus well, and/or has lower cytotoxicity, better in vivo pharmacokinetic properties and in vivo pharmacodynamic properties (extracted from patent WO2020078401A1, compound 13-1) .

HY-143750

Cap-dependent endonuclease-IN-7	Influenza Virus	Infection
Cap-dependent endonuclease-IN-7 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-7 Inhibits the synthesis of viral mRNA and eventually inhibits virus proliferation. Cap-dependent endonuclease-IN-7 has the potential for the research of viral infections (including influenza A, influenza B and influenza C) (extracted from patent WO2020177715A1, compound 5)

HY-143744

Cap-dependent endonuclease-IN-3	Influenza Virus	Infection
Cap-dependent endonuclease-IN-3 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-3 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-3 has the potential for the research of influenza A and influenza B infection (extracted from patent WO2019141179A1, compound VI-1) .

HY-143743

Cap-dependent endonuclease-IN-2	Influenza Virus	Infection
Cap-dependent endonuclease-IN-2 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-2 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-2 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent WO2019052565A1, compound 28) .

HY-143755

Cap-dependent endonuclease-IN-9	Influenza Virus	Infection
Cap-dependent endonuclease-IN-9 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-9 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-9 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent CN112521386A, compound VI-1) .

HY-143757

Cap-dependent endonuclease-IN-10	Influenza Virus	Infection
Cap-dependent endonuclease-IN-10 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-10 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo pharmacokinetic and in vivo pharmacodynamic properties, and better hepatic microsomal stability. Cap-dependent endonuclease-IN-10 has the potential for the research of viral infections (including influenza A, influenza B and influenza C) (extracted from patent WO2021129799A1, compound 1-1) .

HY-163621

Cap-dependent endonuclease-IN-28	Influenza Virus	Infection
Cap-dependent endonuclease-IN-28 (Compound 11) is a potent cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-28 inhibits CEN of TOSV, ANDV, and LACV viruses with IC₅₀ values of 2.4, 0.5, and 4 μM, respectively .

HY-162242

Cap-dependent endonuclease-IN-27	Influenza Virus	Infection
Cap-dependent endonuclease-IN-27 (Compound 8) is an orally active potent cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-27, an antiviral agent, shows activity against influenza B virus. Cap-dependent endonuclease-IN-27 has inhibitory activity against IFV A/WSN/33 (H1N1) polymerase (EC₅₀ = 12.26 nM) .

HY-132894

Pixavir marboxilo	Influenza Virus	Infection
Pixavir marboxilo is an orally active **cap-dependent endonuclease** inhibitor with high potency. Pixavir marboxilo can be used for the research of influenza .

HY-109025A

Baloxavir Maximum Cited Publications 30 Publications Verification Baloxavir acid; S-033447	Influenza Virus	Infection
Baloxavir (Baloxavir acid), derived from the proagent Baloxavir marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir inhibits viral RNA transcription and replication and has potently antiviral activity .

HY-109025AR

Baloxavir (Standard)	Influenza Virus	Infection
Baloxavir (Standard) is the analytical standard of Baloxavir. This product is intended for research and analytical applications. Baloxavir (Baloxavir acid), derived from the proagent Baloxavir marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir inhibits viral RNA transcription and replication and has potently antiviral activity .

HY-153570

Influenza virus-IN-7	Influenza Virus	Infection
Influenza virus-IN-7 (Example 16) is an orally active **cap-dependent endonuclease** inhibitor that can be used for the research of influenza viral infectious diseases .

HY-W751835

Baloxavir-d4 Maximum Cited Publications 30 Publications Verification Baloxavir acid-d₄; S-033447-d₄	Isotope-Labeled Compounds	Others Cancer
Baloxavir-d₄ (Baloxavir acid-d₄; S-033447-d₄) is the deuterium-labeled Baloxavir (HY-109025A). Baloxavir-d₄ (Baloxavir-d₄ acid), derived from the proagent Baloxavir-d₄ marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir-d₄ inhibits viral RNA transcription and replication and has potently antiviral activity .

HY-109025

Baloxavir marboxil Maximum Cited Publications 30 Publications Verification S-033188; RG 6152	Influenza Virus	Infection
Baloxavir marboxil (S-033188) is a selective inhibitor of influenza cap-dependent *endonuclease. Baloxavir marboxil, a potent antiviral agent, shows activity against influenza A* and B virus .

HY-109025R

Baloxavir marboxil (Standard)	Influenza Virus	Infection
Baloxavir marboxil (Standard) is the analytical standard of Baloxavir marboxil. This product is intended for research and analytical applications. Baloxavir marboxil (S-033188) is a selective inhibitor of influenza cap-dependent *endonuclease. Baloxavir marboxil, a potent antiviral agent, shows activity against influenza A* and B virus .

HY-109025AS

Baloxavir-d5 Baloxavir acid-d₅; S-033447-d₅	Isotope-Labeled Compounds Influenza Virus	Infection
Baloxavir-d₅ is deuterium labeled Baloxavir. Baloxavir (Baloxavir acid), derived from the proagent Baloxavir marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir inhibits viral RNA transcription and replication and has potently antiviral activity[1][2].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W751835

Baloxavir-d4 25+ Cited Publications Baloxavir acid-d₄; S-033447-d₄	Classification of Application Fields Disease Research Fields Cancer	Isotope-Labeled Compounds
Baloxavir-d₄ (Baloxavir acid-d₄; S-033447-d₄) is the deuterium-labeled Baloxavir (HY-109025A). Baloxavir-d₄ (Baloxavir-d₄ acid), derived from the proagent Baloxavir-d₄ marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir-d₄ inhibits viral RNA transcription and replication and has potently antiviral activity .

Cat. No.	Product Name	Chemical Structure

HY-W751835

Baloxavir-d4 25+ Cited Publications
Baloxavir-d₄ (Baloxavir acid-d₄; S-033447-d₄) is the deuterium-labeled Baloxavir (HY-109025A). Baloxavir-d₄ (Baloxavir-d₄ acid), derived from the proagent Baloxavir-d₄ marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir-d₄ inhibits viral RNA transcription and replication and has potently antiviral activity .

Baloxavir-d4

25+ Cited Publications

Baloxavir-d₄ (Baloxavir acid-d₄; S-033447-d₄) is the deuterium-labeled Baloxavir (HY-109025A). Baloxavir-d₄ (Baloxavir-d₄ acid), derived from the proagent Baloxavir-d₄ marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir-d₄ inhibits viral RNA transcription and replication and has potently antiviral activity .

HY-109025AS

Baloxavir-d5
Baloxavir-d₅ is deuterium labeled Baloxavir. Baloxavir (Baloxavir acid), derived from the proagent Baloxavir marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir inhibits viral RNA transcription and replication and has potently antiviral activity[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

cap-dependent endonuclease

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products